Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Tennessee Oncology-Chattanooga
mi
from
Chattanooga, TN
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Tennessee Oncology-Chattanooga
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Tennessee Oncology PPLC SCRI
mi
from
Nashville, TN
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Tennessee Oncology PPLC SCRI
mi
from
Nashville, TN
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Texas Oncology
mi
from
Bedford and Grapevine, TX
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Texas Oncology
mi
from
Bedford and Grapevine, TX
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Texas Oncology - Dallas
mi
from
Dallas, TX
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Texas Oncology - Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Texas Oncology - Longview and Tyler
mi
from
Longview and Tyler, TX
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Texas Oncology - Longview and Tyler
mi
from
Longview and Tyler, TX
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Cancer Care Center of South Texas-HOAST
mi
from
New Braunfels and San Antonio, TX
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Cancer Care Center of South Texas-HOAST
mi
from
New Braunfels and San Antonio, TX
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Brooke Army Medical Center
mi
from
San Antonio, TX
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Brooke Army Medical Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Scott and White Healthcare
mi
from
Temple, TX
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Scott and White Healthcare
mi
from
Temple, TX
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
University of TX Health Science Center at Tyler
mi
from
Tyler, TX
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
University of TX Health Science Center at Tyler
mi
from
Tyler, TX
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Northwest Cancer Specialist
mi
from
Vancouver, WA
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Northwest Cancer Specialist
mi
from
Vancouver, WA
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
USC/Norris Comprehensive Cancer Center and LAC/USC Medical Center
mi
from
Los Angeles, CA
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
USC/Norris Comprehensive Cancer Center and LAC/USC Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Rocky Mountain Cancer Centers
mi
from
Multiple Locations, CO
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Rocky Mountain Cancer Centers
mi
from
Multiple Locations, CO
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Montefiore Medical Center
mi
from
The Bronx, NY
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Montefiore Medical Center
mi
from
The Bronx, NY
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Oncology Hematology Consultants PA
mi
from
Fort Worth, TX
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Oncology Hematology Consultants PA
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Texas Oncology - Forth Worth
mi
from
Fort Worth, TX
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Texas Oncology - Forth Worth
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Virginia Oncology Associates
mi
from
Multiple Locations, VA
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Virginia Oncology Associates
mi
from
Multiple Locations, VA
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Royal North Shore Hospital
mi
from
St Leonards,
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Royal North Shore Hospital
mi
from
St Leonards,
Click here to add this to my saved trials
Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer
Phase 1 Study of Sipuleucel-T and Ipilimumab in Combination for Advanced Prostate Cancer
Status: Enrolling
Updated:  8/23/2017
Prostate Oncology Specialists, Inc.
mi
from
Marina Del Rey, CA
Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer
Phase 1 Study of Sipuleucel-T and Ipilimumab in Combination for Advanced Prostate Cancer
Status: Enrolling
Updated: 8/23/2017
Prostate Oncology Specialists, Inc.
mi
from
Marina Del Rey, CA
Click here to add this to my saved trials
Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)
Protocol EC-FV-05: An Open-label, Multi-center, Extension Study of EC145 Administered Weeks 1 and 3 of a 4-Week Cycle in Subjects Enrolled in a Previous Study With EC145
Status: Enrolling
Updated:  8/23/2017
Center for Blood and Cancer Disorders
mi
from
Bethesda, MD
Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)
Protocol EC-FV-05: An Open-label, Multi-center, Extension Study of EC145 Administered Weeks 1 and 3 of a 4-Week Cycle in Subjects Enrolled in a Previous Study With EC145
Status: Enrolling
Updated: 8/23/2017
Center for Blood and Cancer Disorders
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6
A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6
Status: Enrolling
Updated:  8/24/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6
A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6
Status: Enrolling
Updated: 8/24/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer
Phase Ib Dose Escalation and Biomarker Study of MK-2206 in Combination With Standard Doses of Weekly Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors With an Expansion in Advanced Breast Cancer
Status: Enrolling
Updated:  8/24/2017
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer
Phase Ib Dose Escalation and Biomarker Study of MK-2206 in Combination With Standard Doses of Weekly Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors With an Expansion in Advanced Breast Cancer
Status: Enrolling
Updated: 8/24/2017
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer
Phase Ib Dose Escalation and Biomarker Study of MK-2206 in Combination With Standard Doses of Weekly Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors With an Expansion in Advanced Breast Cancer
Status: Enrolling
Updated:  8/24/2017
M D Anderson Cancer Center
mi
from
Houston, TX
MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer
Phase Ib Dose Escalation and Biomarker Study of MK-2206 in Combination With Standard Doses of Weekly Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors With an Expansion in Advanced Breast Cancer
Status: Enrolling
Updated: 8/24/2017
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer
Phase Ib Dose Escalation and Biomarker Study of MK-2206 in Combination With Standard Doses of Weekly Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors With an Expansion in Advanced Breast Cancer
Status: Enrolling
Updated:  8/24/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer
Phase Ib Dose Escalation and Biomarker Study of MK-2206 in Combination With Standard Doses of Weekly Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors With an Expansion in Advanced Breast Cancer
Status: Enrolling
Updated: 8/24/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)
Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)
Status: Enrolling
Updated:  8/24/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)
Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)
Status: Enrolling
Updated: 8/24/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Accelerated Intensity Modulated Radiation Therapy (AIMRT) to the Breast After Segmental Mastectomy
Accelerated Intensity Modulated Radiation Therapy (AIMRT) to the Breast After Segmental Mastectomy: a Pilot Study
Status: Enrolling
Updated:  8/24/2017
NYU Langone Medical Center
mi
from
New York, NY
Accelerated Intensity Modulated Radiation Therapy (AIMRT) to the Breast After Segmental Mastectomy
Accelerated Intensity Modulated Radiation Therapy (AIMRT) to the Breast After Segmental Mastectomy: a Pilot Study
Status: Enrolling
Updated: 8/24/2017
NYU Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
MRI Adaptive Replanning Using ViewRay
A Study of Adaptive Radiotherapy Using ViewRay MRI Based Imaging in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  8/24/2017
University of Miami
mi
from
Miami, FL
MRI Adaptive Replanning Using ViewRay
A Study of Adaptive Radiotherapy Using ViewRay MRI Based Imaging in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 8/24/2017
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.
Assessment of Liver Cancer Response to Transcatheter Arterial Chemoembolization (TACE) Using Functional Triple-Phase MultiHance-Enhanced Magnetic Resonance Imaging (MRI)
Status: Enrolling
Updated:  8/28/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.
Assessment of Liver Cancer Response to Transcatheter Arterial Chemoembolization (TACE) Using Functional Triple-Phase MultiHance-Enhanced Magnetic Resonance Imaging (MRI)
Status: Enrolling
Updated: 8/28/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Early Prediction of Pathology Response of Chemoradiotherapy With FLT PET
Early Prediction of Pathology Response of Chemoradiotherapy With FLT PET
Status: Enrolling
Updated:  8/28/2017
Columbia University Medical Center
mi
from
New York, NY
Early Prediction of Pathology Response of Chemoradiotherapy With FLT PET
Early Prediction of Pathology Response of Chemoradiotherapy With FLT PET
Status: Enrolling
Updated: 8/28/2017
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens
Status: Enrolling
Updated:  8/28/2017
Donald W. Hill, M.D., F.A.C.P.
mi
from
Casa Grande, AZ
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens
Status: Enrolling
Updated: 8/28/2017
Donald W. Hill, M.D., F.A.C.P.
mi
from
Casa Grande, AZ
Click here to add this to my saved trials
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens
Status: Enrolling
Updated:  8/28/2017
New York Oncology Heamatology - Latham
mi
from
Clifton Park, NY
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens
Status: Enrolling
Updated: 8/28/2017
New York Oncology Heamatology - Latham
mi
from
Clifton Park, NY
Click here to add this to my saved trials
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens
Status: Enrolling
Updated:  8/28/2017
Texas Oncology-Paris
mi
from
Paris, TX
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens
Status: Enrolling
Updated: 8/28/2017
Texas Oncology-Paris
mi
from
Paris, TX
Click here to add this to my saved trials
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens
Status: Enrolling
Updated:  8/28/2017
Texas Oncology, P.A. - Plano
mi
from
Plano, TX
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens
Status: Enrolling
Updated: 8/28/2017
Texas Oncology, P.A. - Plano
mi
from
Plano, TX
Click here to add this to my saved trials
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens
Status: Enrolling
Updated:  8/28/2017
Texas Oncology-Waco
mi
from
Waco, TX
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens
Status: Enrolling
Updated: 8/28/2017
Texas Oncology-Waco
mi
from
Waco, TX
Click here to add this to my saved trials
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens
Status: Enrolling
Updated:  8/28/2017
Arizona Oncology Associates, PC - HOPE
mi
from
Tucson, AZ
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens
Status: Enrolling
Updated: 8/28/2017
Arizona Oncology Associates, PC - HOPE
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens
Status: Enrolling
Updated:  8/28/2017
Ronald Yanagihara, MD 9360 North Name Uno Suite 130 Gilroy California 95020
mi
from
Gilroy, CA
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens
Status: Enrolling
Updated: 8/28/2017
Ronald Yanagihara, MD 9360 North Name Uno Suite 130 Gilroy California 95020
mi
from
Gilroy, CA
Click here to add this to my saved trials
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens
Status: Enrolling
Updated:  8/28/2017
Ocala Oncology Center Pl
mi
from
Ocala, FL
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens
Status: Enrolling
Updated: 8/28/2017
Ocala Oncology Center Pl
mi
from
Ocala, FL
Click here to add this to my saved trials
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens
Status: Enrolling
Updated:  8/28/2017
Montefiore Medical Park 1695 Easchester Road Floor 1 Bronx, NY 10461
mi
from
New York, NY
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens
Status: Enrolling
Updated: 8/28/2017
Montefiore Medical Park 1695 Easchester Road Floor 1 Bronx, NY 10461
mi
from
New York, NY
Click here to add this to my saved trials
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens
Status: Enrolling
Updated:  8/28/2017
Cancer Treatment and Research Centre Bismarck North Dakota 58501
mi
from
Bismarck, ND
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens
Status: Enrolling
Updated: 8/28/2017
Cancer Treatment and Research Centre Bismarck North Dakota 58501
mi
from
Bismarck, ND
Click here to add this to my saved trials
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens
Status: Enrolling
Updated:  8/28/2017
OLV Ziekenhuis
mi
from
Aalst,
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens
Status: Enrolling
Updated: 8/28/2017
OLV Ziekenhuis
mi
from
Aalst,
Click here to add this to my saved trials
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens
Status: Enrolling
Updated:  8/28/2017
Washington University 660 South Euclid Avenue Campus Box 8124 St Louis Missouri 63110
mi
from
Saint Louis, MO
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens
Status: Enrolling
Updated: 8/28/2017
Washington University 660 South Euclid Avenue Campus Box 8124 St Louis Missouri 63110
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Shared Decision Making in Low Risk Prostate Cancer
Shared Decision Making: A Study Assessing the Benefit of a Web Based Aid Presenting Treatment Options for Patients With Low Risk Prostate Cancer
Status: Enrolling
Updated:  8/28/2017
Massachusetts General Hospital
mi
from
Boston, MA
Shared Decision Making in Low Risk Prostate Cancer
Shared Decision Making: A Study Assessing the Benefit of a Web Based Aid Presenting Treatment Options for Patients With Low Risk Prostate Cancer
Status: Enrolling
Updated: 8/28/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Status: Enrolling
Updated:  8/28/2017
Emory University Hospital
mi
from
Atlanta, GA
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Status: Enrolling
Updated: 8/28/2017
Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Status: Enrolling
Updated:  8/28/2017
North Shore-LIJ Health System
mi
from
Manhasset, NY
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Status: Enrolling
Updated: 8/28/2017
North Shore-LIJ Health System
mi
from
Manhasset, NY
Click here to add this to my saved trials
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Status: Enrolling
Updated:  8/28/2017
Columbia University Medical Center
mi
from
New York, NY
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Status: Enrolling
Updated: 8/28/2017
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Status: Enrolling
Updated:  8/28/2017
Temple University Hospital
mi
from
Philadelphia, PA
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Status: Enrolling
Updated: 8/28/2017
Temple University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pilot Study: Combined Molecular Breast Imaging/Ultrasound System for Diagnostic Evaluation of MBI-detected Lesions
Pilot Study: Combined Molecular Breast Imaging/Ultrasound System for Diagnostic Evaluation of MBI-detected Lesions
Status: Enrolling
Updated:  8/28/2017
The Mayo Clinic
mi
from
Rochester, MN
Pilot Study: Combined Molecular Breast Imaging/Ultrasound System for Diagnostic Evaluation of MBI-detected Lesions
Pilot Study: Combined Molecular Breast Imaging/Ultrasound System for Diagnostic Evaluation of MBI-detected Lesions
Status: Enrolling
Updated: 8/28/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Utilizing Advance Care Planning Videos to Empower Perioperative Cancer Patients and Families
Utilizing Advance Care Planning Videos to Empower Perioperative Cancer Patients and Families
Status: Enrolling
Updated:  8/28/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
Utilizing Advance Care Planning Videos to Empower Perioperative Cancer Patients and Families
Utilizing Advance Care Planning Videos to Empower Perioperative Cancer Patients and Families
Status: Enrolling
Updated: 8/28/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids
Phase 1A/B Study of Combination Carboplatin, Paclitaxel and Ridaforolimus in Patients With Solid, Endometrial, and Ovarian Cancers
Status: Enrolling
Updated:  8/29/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids
Phase 1A/B Study of Combination Carboplatin, Paclitaxel and Ridaforolimus in Patients With Solid, Endometrial, and Ovarian Cancers
Status: Enrolling
Updated: 8/29/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of SU11248 (Sutent) in Combination With Metronomic Dosing of Cyclophosphamide and Methotrexate in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  8/30/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of SU11248 (Sutent) in Combination With Metronomic Dosing of Cyclophosphamide and Methotrexate in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 8/30/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials